Publications

Cancers

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.

02-08-2022

Medical image analysis

DeepSMILE: Contrastive self-supervised pre-training benefits MSI and HRD classification directly from H&E whole-slide images in colorectal and breast cancer.

01-07-2022

British journal of cancer

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.

01-07-2022

NPJ breast cancer

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

28-04-2022

Virchows Archiv : an international journal of pathology

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

01-04-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022

NPJ breast cancer

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

01-12-2021

NPJ breast cancer

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

20-10-2021

Cancers

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

29-09-2021

Nature communications

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.

27-09-2021

JNCI cancer spectrum

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.

01-06-2021

The journal of pathology. Clinical research

Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.

01-05-2021

Virchows Archiv : an international journal of pathology

Correction to: The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of neoadjuvant chemotherapy.

01-03-2021

Cancers

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer.

16-01-2021

Key Publication

Cancer treatment reviews

Erratum to "Prognostic factors in patients with oligometastatic breast cancer - A systematic review". [Cancer treatment Rev. 91 (2020) 102114].

01-01-2021

Cancer treatment reviews

Prognostic factors in patients with oligometastatic breast cancer - A systematic review.

01-12-2020

Virchows Archiv : an international journal of pathology

The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.

01-10-2020

Nature communications

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

07-08-2020

Molecular cancer research : MCR

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

01-07-2020

NPJ breast cancer

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

22-05-2020

NPJ breast cancer

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

16-05-2020

NPJ breast cancer

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

16-05-2020

Cancer discovery

Characteristics and Outcome of AKT1^E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.

01-04-2020

Journal of the Endocrine Society

Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors.

01-04-2020

European journal of cancer (Oxford, England : 1990)

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

01-03-2020

Breast cancer research : BCR

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

26-12-2019

Breast cancer research : BCR

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.

07-08-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

BMC cancer

A specific gene expression signature for visceral organ metastasis in breast cancer.

08-04-2019

Breast cancer research and treatment

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior.

01-04-2019

Breast cancer research : BCR

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

15-02-2019

Cell

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

07-02-2019

Human reproduction (Oxford, England)

Iatrogenic endometriosis harbors somatic cancer-driver mutations.

01-01-2019

Oncoimmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

14-12-2018

Cell

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

31-05-2018

JCO precision oncology

Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

01-11-2017

Advances in anatomic pathology

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

01-11-2017

Nature

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

07-09-2017

Advances in anatomic pathology

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

01-09-2017

Oncotarget

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

15-08-2017

BMC cancer

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer.

07-02-2017

Oncotarget

Identification of breast cancer cell subtypes sensitive to ATG4B inhibition.

11-10-2016

BMC cancer

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.

02-08-2016

International journal of cancer

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

15-03-2015

Oncogene

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

22-01-2015

Gynecologic oncology

Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary.

01-09-2014

Breast cancer research and treatment

Genomic profiling of histological special types of breast cancer.

01-11-2013

The Journal of pathology

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

01-07-2013

Proceedings of the National Academy of Sciences of the United States of America

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

26-03-2013

External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.

DeepSMILE: Contrastive self-supervised pre-training benefits MSI and HRD classification directly from H&E whole-slide images in colorectal and breast cancer.

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women.

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.

Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease.

Correction to: The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of neoadjuvant chemotherapy.

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer.

Erratum to "Prognostic factors in patients with oligometastatic breast cancer - A systematic review". [Cancer treatment Rev. 91 (2020) 102114].

Prognostic factors in patients with oligometastatic breast cancer - A systematic review.

The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.

Functional Profiling of FSH and Estradiol in Ovarian Granulosa Cell Tumors.

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

A specific gene expression signature for visceral organ metastasis in breast cancer.

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior.

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Iatrogenic endometriosis harbors somatic cancer-driver mutations.

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer.

Identification of breast cancer cell subtypes sensitive to ATG4B inhibition.

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

Development and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovary.

Genomic profiling of histological special types of breast cancer.

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

This site uses cookies

Characteristics and Outcome of AKT1^E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.